Irhythm Technologies (NASDAQ: IRTC) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Irhythm Technologies to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.
This is a breakdown of current recommendations for Irhythm Technologies and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Irhythm Technologies Competitors||491||1884||3747||116||2.56|
Irhythm Technologies presently has a consensus target price of $71.17, indicating a potential upside of 12.80%. As a group, “Surgical & medical instruments” companies have a potential upside of 8.10%. Given Irhythm Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe Irhythm Technologies is more favorable than its competitors.
This table compares Irhythm Technologies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Irhythm Technologies Competitors||-62.26%||-47.35%||-18.28%|
Insider and Institutional Ownership
98.6% of Irhythm Technologies shares are held by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 23.3% of Irhythm Technologies shares are held by company insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Irhythm Technologies has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Irhythm Technologies’ competitors have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.
Valuation & Earnings
This table compares Irhythm Technologies and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Irhythm Technologies||$98.51 million||-$29.42 million||-48.53|
|Irhythm Technologies Competitors||$1.54 billion||$111.80 million||-146.17|
Irhythm Technologies’ competitors have higher revenue and earnings than Irhythm Technologies. Irhythm Technologies is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Irhythm Technologies beats its competitors on 9 of the 13 factors compared.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. Its Zio XT monitor, a single-use, wire-free, and wearable patch-based biosensor, records patient's heartbeats and ECG data. The company was founded in 2006 and is headquartered in San Francisco, California.
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.